Matt D T Hitchings
Overview
Explore the profile of Matt D T Hitchings including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
1253
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Crisp A, Halloran M, Hitchings M, Longini I, Dean N
BMC Med Res Methodol
. 2025 Jan;
25(1):16.
PMID: 39844041
Background: Cluster randomized trials, which often enroll a small number of clusters, can benefit from constrained randomization, selecting a final randomization scheme from a set of known, balanced randomizations. Previous...
2.
Kostandova N, Schluth C, Arambepola R, Atuhaire F, Berube S, Chin T, et al.
Nat Commun
. 2024 Dec;
15(1):10504.
PMID: 39627231
The emergence of SARS-CoV-2 into a highly susceptible global population was primarily driven by human mobility-induced introduction events. Especially in the early stages, understanding mobility was vital to mitigating the...
3.
Amin A, Hitchings M, Ranzani O, Andrews J, Cummings D, Ko A, et al.
Am J Epidemiol
. 2024 Aug;
PMID: 39191656
Test-negative designs are increasingly used to evaluate vaccine effectiveness because of desirable properties like reduced confounding due to healthcare-seeking behaviors and lower cost compared to other study designs. An individual's...
4.
Lazar Neto F, Hitchings M, Amin A, de Franca G, Lind M, Scaramuzzini Torres M, et al.
Lancet Reg Health Am
. 2024 May;
34:100755.
PMID: 38737773
Background: The emergence of COVID-19 variants with immune scape and the waning of primary vaccine schemes effectiveness have prompted many countries to indicate first and second booster COVID-19 vaccine doses...
5.
Hitchings M, Berthe F, Aruna P, Shehu I, Hamza M, Nanama S, et al.
PLoS Med
. 2024 Mar;
21(3):e1004370.
PMID: 38507664
[This corrects the article DOI: 10.1371/journal.pmed.1003923.].
6.
Haller M, Rubin D, Hitchings M
J Gen Intern Med
. 2024 Mar;
39(8):1488-1491.
PMID: 38499724
COVID-19 vaccination is estimated to have averted more than 2.4 million deaths globally. In the United States (U.S.) alone, more than 120,000 deaths and 700,000 hospitalizations are reportedly estimated to...
7.
Lind M, Dorion M, Houde A, Lansing M, Lapidus S, Thomas R, et al.
Nat Commun
. 2023 Aug;
14(1):5055.
PMID: 37598213
Whether SARS-CoV-2 infection and COVID-19 vaccines confer exposure-dependent ("leaky") protection against infection remains unknown. We examined the effect of prior infection, vaccination, and hybrid immunity on infection risk among residents...
8.
Adams L, Hitchings M, Medina F, Rodriguez D, Sanchez-Gonzalez L, Moore H, et al.
Am J Trop Med Hyg
. 2023 Jun;
109(2):413-419.
PMID: 37308104
Limited dengue virus (DENV) seroprevalence estimates are available for Puerto Rico, which are needed to inform the potential use and cost-effectiveness of DENV vaccines. The Communities Organized to Prevent Arboviruses...
9.
Hitchings M, Patel E, Khan R, Srikrishnan A, Anderson M, Kumar K, et al.
Am J Epidemiol
. 2023 Apr;
192(9):1552-1561.
PMID: 37084085
Serological assays used to estimate the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) often rely on manufacturers' cutoffs established on the basis of severe cases. We conducted a...
10.
Garcia-Carreras B, Hitchings M, Johansson M, Biggerstaff M, Slayton R, Healy J, et al.
Nat Commun
. 2023 Apr;
14(1):2235.
PMID: 37076502
Reconstructing the incidence of SARS-CoV-2 infection is central to understanding the state of the pandemic. Seroprevalence studies are often used to assess cumulative infections as they can identify asymptomatic infection....